Latest Conference Articles

New findings suggest the common ophthalmic disorder in premature infants could be three-fold more prevalent in multiracial infants.

In data presented at AAO, investigators examine the impact of anti-VEGF injections on ocular hypertension.

New AAO 2020 findings suggest even geographical differences could define retinal detachment risks among nearsighted patients.

In data presented at AAO, investigators find BI 836680 shows early signals of bioactivity.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

The study presented at AAO provides an update on previously shared 6-month data from earlier this year.

Raymond Douglas, MD, PhD, discusses data that demonstrate the benefit of teprotumumab in patients with all levels of thyroid eye disease.

Edmund Tsui, MD, talks the new AAO 2020 virtual format as well as presentations that have particularly caught his attention.

Longer studies are needed to determine the effectiveness and durability of CDI interventions.

Favorable phase 2 results with the TYK2 inhibitor for psoriatic arthritis at ACR 2020 coincided with announced positive phase 3 trial results for psoriasis.

A secukinumab researcher explains why the practice may become the "next stethoscope" of medicine.

New findings show a unique series of markers could indicate particular black SLE patient risks.

Researchers have been unable to leverage new technology for ADHD screening.

Dr. David Goodman discusses the gaps in ADHD treatment.

A real-world study shows the therapy was slightly more efficacious for biologic-naive PsA patients.

A systematic review suggests patients taking immunosuppressive therapy may not be at as heightened risk of infection as previously thought.

An interview with a study author on the promising findings, and the use of ultrasonography in assessing psoriatic arthritis treatment.

Children hospitalized from the condition face a 14-fold increased risk of MACE.

The world is suddenly fixed on the field's most promising agents for an unprecedented virus. It's created a unique situation for specialists to collaborate.

The common rheumatic drug was found in a cohort analysis to be linked to greater regional TB outbreaks.

Researchers find 1 lipid class and 6 miRNAs differed significantly between different treatment groups.

It is possible to diagnose patients with ADHD as young as 2 years old.

AXS-05 significantly relieved agitation, demonstrating a change from baseline in the CMAI total score of 15.4 compared to 11.5 for the placebo.

Less than 2% of surveyed families with rheumatic-disease children had reported a COVID-19 case in the early pandemic—and even fewer had physician-confirmed symptoms.

Treatment for ADHD is similar for adolescents and adult patients.

Dr. David Goodman will present 5 times during NEI about different ADHD issues and topics.

In the study, investigators tested the impact of the study drug in a rerandomized patient population that previously received a placebo.

A discussion on how the pandemic has burdened and, in some ways, bettered the very involved specialty.

The monoclonal antibody has built on its 18-month portfolio with sustained renal benefits for the at-need patient group.